Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (23.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensa |
| 06.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ereto, which is incorporated herein by reference. Item 5.02 – Departure of Directors or Certain Officers; Election of Di |
| 15.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Cert |
| 07.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | equirements of the Securities Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointm |
Stammdaten
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Unternehmen & Branche
| Name | Damora Therapeutics, Inc. |
|---|---|
| Ticker | GLTO |
| CIK | 0001800315 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 37,5 Mio. USD |
| Beta | 1,57 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -209,839,000 | 3.98 | 260,527,000 | 240,380,000 | |
| 2025-09-30 | 10-Q | -3,133,000 | -2.36 | 10,736,000 | 8,007,000 | |
| 2025-06-30 | 10-Q | -3,437,000 | -2.60 | 13,691,000 | 10,953,000 | |
| 2025-03-31 | 10-Q | -2,533,000 | -1.92 | 15,365,000 | 13,709,000 | |
| 2024-12-31 | 10-K | -21,439,000 | -18.53 | 17,132,000 | 15,831,000 | |
| 2024-09-30 | 10-Q | -3,883,000 | -3.39 | 23,376,000 | 20,935,000 | |
| 2024-06-30 | 10-Q | -5,338,000 | -4.92 | 27,297,000 | 23,588,000 | |
| 2024-03-31 | 10-Q | -5,477,000 | -5.05 | 32,477,000 | 28,159,000 | |
| 2023-12-31 | 10-K | -38,349,000 | -36.08 | 38,227,000 | 32,331,000 | |
| 2023-09-30 | 10-Q | -8,136,000 | -7.50 | 50,049,000 | 37,382,000 | |
| 2023-06-30 | 10-Q | -10,744,000 | -0.41 | 58,803,000 | 43,700,000 | |
| 2023-03-31 | 10-Q | -12,994,000 | -0.51 | 64,630,000 | 50,333,000 | |
| 2022-12-31 | 10-K | -61,624,000 | -2.43 | 73,188,000 | 61,753,000 | |
| 2022-09-30 | 10-Q | -13,730,000 | -0.54 | 82,025,000 | 72,727,000 | |
| 2022-06-30 | 10-Q | -16,887,000 | -0.67 | 92,858,000 | 85,065,000 | |
| 2022-03-31 | 10-Q | -16,938,000 | -0.67 | 108,930,000 | 101,314,000 | |
| 2021-12-31 | 10-K | -51,752,000 | -2.05 | 122,215,000 | 117,223,000 | |
| 2021-09-30 | 10-Q | -12,696,000 | -0.50 | 135,874,000 | 129,620,000 | |
| 2021-06-30 | 10-Q | -12,302,000 | 146,822,000 | 141,432,000 | ||
| 2021-03-31 | 10-Q | -13,345,000 | 158,655,000 | 152,571,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Schambye Hans T. | Director, Officer, Chief Executive Officer | Open Market Sale | -700 | 21.38 | -14,966.00 | -330,5% | |
| 2026-01-02 | Winslow Garrett | Officer, General Counsel | Open Market Sale | -255 | 21.38 | -5,451.90 | -120,4% | |
| 2026-01-02 | Firmani Lori | Officer, Chief Financial Officer | Open Market Sale | -135 | 21.41 | -2,890.35 | -63,8% | |
| 2025-07-03 | Schambye Hans T. | Director, Officer, Chief Executive Officer | Open Market Sale | -735 | 3.38 | -2,484.30 | -54,9% | |
| 2025-07-03 | Winslow Garrett | Officer, General Counsel | Open Market Sale | -260 | 3.39 | -881.40 | -19,5% | |
| 2025-07-03 | Firmani Lori | Officer, Interim CFO | Open Market Sale | -147 | 3.39 | -498.33 | -11,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.